Evaluation of mucilage of Hibiscus rosasinensis Linn as rate controlling matrix for sustained release of diclofenac.
This article reports the exploitation of novel hydrophilic excipient, that is, mucilage from Hibiscus rosasinensis Linn, for the development of sustained release tablet. Swelling ratio and flow properties analyses of dried mucilage powder were carried out. A 3(2) full factorial design was used. In factorial design, amounts of dried mucilage and dibasic calcium phosphate (DCP) were taken as independent factors and percentage drug release in 60 and 300 min and time for 80% drug release as dependent variables. Matrix tablet containing dried mucilage and diclofenac sodium (DS) was prepared through direct compression techniques. DS tablets were evaluated for hardness, friability, weight variation, in vitro drug release and water uptake, and mass loss study. The dried mucilage powder shows superior swelling capacity and excellent flow properties. Prepared tablets have acceptable hardness, friability, and uniformity in weight. It was found that batch HD8 fulfills all selected criteria. Drug release kinetics from these formulations corresponded best to the zero-order kinetics. Water uptake was independent whereas mass loss was dependent on agitation speed. The concept of similarity factor (f(2)) was used to prove similarity of dissolution profile in distilled water and phosphate buffer and was found to be 90.68. It was concluded that mucilage can be used as release-retarding agent for 12 h when the drug-mucilage ratio was 1:1.5. So, matrix tablet containing dried mucilage is most suitable for sustained release of DS.
Jani
Girish K
GK
K. B. Raval College of Pharmacy, Gandhinagar, Gujarat, India. girishkjani2002@yahoo.com
Shah
Dhiren P
DP
D000269:Adhesives / Q000302:isolation & purification* / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000737:chemistry / Q000633:toxicity; D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003692:Delayed-Action Preparations; D004008:Diclofenac / Q000008:administration & dosage* / Q000737:chemistry / Q000633:toxicity; D016503:Drug Delivery Systems; D005079:Excipients / Q000302:isolation & purification / Q000494:pharmacology; D031584:Hibiscus; D007928:Lethal Dose 50; D010936:Plant Extracts; D018515:Plant Leaves; D051381:Rats; D017208:Rats, Wistar; D013607:Tablets
D000269:Adhesives; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D005079:Excipients; D010936:Plant Extracts; D013607:Tablets; D004008:Diclofenac